Hos patienter, der kun fik INVANZ, var de mest almindelige bivirkninger under behandling samt 14 dages follow- up efter behandlingen seponeredes: diarré (5, 2%) og smerte ved infusionsstedet (6, 1%).
For patients who received only INVANZ, the most common adverse reactions reported during therapy plus follow-up for 14 days after treatment was stopped were: diarrhoea (5.2%) and infusion site pain (6.1%).